Tela Bio Inc (TELA)
Tela Bio, Inc. is a commercial-stage medical technology company focused on soft-tissue reconstruction solutions designed to support the preservation and restoration of patient anatomy. Its product portfolio includes OviTex Reinforced Tissue Matrix products for hernia repair and abdominal wall reconstruction, as well as OviTex PRS products for plastic and reconstructive surgery. The company also offers OviTex for Laparoscopic and Robotic Procedures, a reinforced tissue matrix derived from ovine rumen with polypropylene fiber for use in laparoscopic and robotic-assisted hernia repairs. Tela Bio markets its products primarily in the United States through a direct sales force. Incorporated in 2012 and headquartered in Malvern, Pennsylvania, the company’s common stock trades on the NASDAQ under the symbol TELA.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TELA
|
$0.98
|
34.8% Upside
|
Undervalued
|
$2.25
|
209.1% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-0.8x
|
-6.2x
|
0.4x
|
32.236 M
|
50.477 M
|
64.2%
|
44.5%
|
-7.7
|
—
|
75.8%
|
